Award
NIH Reporter #5R01AG092949-02
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants
Recipient
INSTITUTE FOR MOLECULAR MEDICINE
Award Amount
$4,923,453.00
Ceiling
$4,923,453.00
Awarded
August 25, 2026
Identifier
5R01AG092949-02
This award funds a multicenter Phase 1 clinical trial to evaluate the safety and immunogenicity of a preventive tau vaccine for preclinical Alzheimer's disease participants. The project is led by the National Institute on Aging and the Institute for Molecular Medicine.
Description
A research grant opportunity for a clinical trial related to Alzheimer's disease involving evaluation of the safety and immunogenicity of a preventive tau vaccine. Managed by the National Institute on Aging (NIA) and the Institute for Molecular Medicine in Huntington Beach, CA.